Astal Laboratories Ltd (512600)

📊 Quarterly Results (₹ Cr)

Astal Laboratories has experienced volatile financial performance, with revenue peaking at ₹134 crore in Q4FY26 (Mar 2026) and then declining to ₹101 crore in the latest quarter (Jun 2026), while operating profit dropped from ₹9 crore to ₹11 crore despite lower revenue, suggesting margin improvement may be offset by volume contraction. Net profit remained flat at ₹9 crore in Jun 2026 compared to ₹8 crore in Mar 2026, but this stability masks underlying weakness in top-line growth. The sharp rise in operating margin from 6.6% in Dec 2025 to 11.3% in Jun 2026 was driven by cost control or lower input costs, but the sustainability of this trend is uncertain given the sequential revenue decline. EPS held steady at ₹2.19, but the lack of growth raises concerns about reinvestment capacity.

🔮 Management Outlook & What's Next

There is no forward guidance or strategic outlook disclosed in the latest available filings, including the June 2026 financial results and the August 31, 2026 board meeting notice. Management has not provided commentary on future revenue expectations, margin targets, or capital allocation plans in the reviewed disclosures. The absence of guidance suggests either a lack of visibility or a focus on operational continuity rather than strategic expansion. Investors should note that no new product launches, capacity expansions, or market entries were referenced in the recent regulatory filings.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

The balance sheet shows a dramatic turnaround in financial scale, with total assets growing from ₹63 crore in Mar 2025 to ₹518 crore in Mar 2026, driven by a surge in equity (from ₹10 to ₹42 crore) and reserves (from ₹26 to ₹292 crore), while borrowings remained low at ₹50 crore. This suggests significant capital infusion, possibly through a fresh equity issue or revaluation, which has strengthened the capital base. However, the company remains asset-light with minimal debt, and the sharp increase in equity may reflect dilution or reclassification rather than organic growth. The capital structure appears conservative, with low leverage (D/E of 0.41), but the sustainability of this growth trajectory depends on operational performance matching the expanded asset base.

💰 Cash Flow Statement (₹ Cr)

👥 Shareholding Pattern

Promoter holding has collapsed from 18.19% in Q3FY26 to 4.53% in Q1FY27, indicating a complete exit or significant dilution, while public shareholding has risen to 80.88% with a growing number of shareholders (3,274). FII and DII holdings remain at 0%, suggesting limited institutional interest or access. The rising shareholder base and low promoter stake may increase governance scrutiny and volatility in trading. The lack of institutional accumulation could signal limited confidence from large investors, despite the company's strong ROE and ROCE, potentially due to the revenue decline and governance changes.

⚖️ Peer Comparison — Pharmaceuticals

🔗 Peer Stock Analyses

⚠️ Risk Factors

1. Persistent revenue decline and margin volatility in core operations, with no visible recovery path disclosed in management commentary. 2. Complete exit of promoter stake may signal loss of confidence or strategic shift, increasing governance and continuity risks. 3. Lack of forward guidance or strategic updates despite strong historical profitability, leaving investors without clarity on growth drivers. 4. High concentration in a narrow shareholder base post-promoter exit, with 80.88% held by dispersed public shareholders, potentially leading to low liquidity and elevated volatility.

📋 Recent Filings

• 🔴 Announcement2026-09-30Astal Laboratories announced the appointment of M/s Avnesh Jain & Co. as cost auditor, M/s Mahendra Khandelwal & Co. as secretarial auditor, and M/s P…
• 🔴 Announcement2026-09-30Astal Laboratories announced the appointment of Ms. Ambika Kedia as Company Secretary and Compliance Officer in its wholly owned subsidiary Pharmachem…
• Announcement2026-09-30Astal Laboratories announced that its trading window will close on October 1, 2026, for all insiders until 48 hours after the unaudited Q3 results rel…
• 🟡 Board Meeting2026-09-29Astal Laboratories held its 33rd Annual General Meeting on 29th September 2026 via video conferencing, with 31 shareholders participating. The meeting…
• 🔴 Insider Trading2026-09-11Astal Laboratories Ltd informed BSE of a disclosure from promoter ACESO RESEARCH LABS LLP regarding share purchases under SEBI PIT Regulations. The fi…
• 🔴 annual report2026-09-07Astal Laboratories Ltd (BSE: 512600) filed its FY 2025-26 annual report on 2026-09-07, reporting total assets of **₹39,957.20 lakhs** (up from ₹6,334.…
• 🟡 Board Meeting2026-09-07Astal Laboratories Limited announced its 33rd Annual General Meeting scheduled for Tuesday, 29 September 2026 at 01:30 P.M. via Video Conferencing/OAV…
• 🔴 annual report2026-09-07Astal Laboratories announced that its FY2025-26 Annual Report and notice of the 33rd AGM scheduled for 29 September 2026 are available via web link an…
• 🟡 Board Meeting2026-09-05Astal Laboratories announced its 33rd Annual General Meeting will be held on September 29, 2026 via video conference, with record dates for shareholde…
• 🟡 Board Meeting2026-09-05Astal Laboratories appointed Avnesh Jain & Co. as its Cost Auditor for FY 2026-27 following a board meeting on September 4, 2026. The appointment is a…

🧠 Analyst's Read

Astal Laboratories is undergoing a structural transition with weakening operational momentum despite a strong balance sheet and historically high returns, and without clear management guidance or strategic direction, the company remains a high-uncertainty holding where execution risk and governance stability are key near-term concerns.

Based on filing content and financial data. Not a recommendation.